Biomedical Research Foundation Academy Of AthensAcademy Of Athens
Scientific Personnel

Dimitrios Dimitrios Roukos, MD, PhD
University Faculty, Affiliated Investigator


Center :

Systems Biology


Brief Bio

Medical  & Academic Titles
 
BIOMEDICAL RESEARCH
1983 - Traditional research: “central dogma” of linear relationship & experimentation, one cause (gene / protein) one outcome (phenotype or disease) (reductionism).
2007 - 1980 Ptychion Iatrikis Medical School of Athens
2007 - 1988 PhD (Dr.med.) of J.W.Goethe-Universitaet Frankfurt aM
2007 - 1988 Recognition by DI.KA.TSA (Act No. 10/47, Ref 7275)
2007 - 1988 Specialist qualification in General Surgery in Greece.
  Clinical cancer genome: Focus on understanding dynamics of heterogeneity, Impact of noncoding regulatory DNA on protein-coding genes, biocircuits and evolution in response to therapy by multiple serial spatiotemporal NGS-based sampling analysis including ctDNA. This patient-derived comprehensive cancer genome mutational and functional landscape is fundamental in the clinic. Linking this Comprehensove in time and space genome-scale personalized information with clinicopathologic and treatment data can provide unprecedented insights into transcriptome and genome-scaleand biocircits dysregulation  dynamics. These future developments pave a rational way for personalized therapies with next-generation transcripttional networks-based drugs.
 
SCIENTIFIC & ADMINISTRATIVE RESPONSIBILITY POSITIONS
2012 - President of the scientific committee and scientific director of the "Center for BioSystems & Genomic Network Medicine "(CBS. GenNetMed).
2006 - Leader, Translational Research, European Network of Excellence (EUNE) for Gastric Cancer
 
Evaluator with honorarium (large scale research innovation programs)
2011 - 2012 E.U. (Health-FP7-INNOVATION-1-2-Systems Medicine and Personalized Medicine
2011 - today FRANCE
2011 France "Agence Nationale de la Recherche" (ANR) research projects (Equipex)
2012 - "Institut National de la Santé et de la Recherche Médicale" (INSERM) of 'Physique-Cancer' Program.
2013 - Cancer TMOI of the French National Alliance for Life and Health Sciences (AVIESAN), Epigenetics and Cancer
2012 - ITALY
Italy [Ministry for Education University and Research (MIUR)]
2014 - BELGIUM (FRS-FNRS)
2000 - Multiple small research projects from European and Asian countries.
2000 - Reviewer in high-impact journals:  Nat Rev Gen (2014), Lancet Oncology, Nat Rev Clin Oncol
 
Editor, Assoc. Editor in the Editorial Board of peer-reviewed journals
2002 - Editor (2), Assoc. Editor (9) in international peer-reviewed journals
 
Lectures - International scientific meetings
1999 - Invited speaker, chairman / coordinator, member of scientific committee and member in consensus panels experts meetings (total> 100).
   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 


 

Selected Publications

Publications:   206 (PubMed, Single, first or leading author: > 170 papers)), 235 (Scopus)
Editor of 2 eBooks: 1. Personalized Cancer Management. 2.Next-generation molecular diagnostics (Publisher: Future Science   
Total sum of impact factors (IF) according to (ISI) Journals:   >  1070
Citations: 7000 with h 67 (Scopus) and 5300 with h 60 (ISI Web of Science).
Updated: May, 2014.     


Roukos DH. Genome network medicine: innovation to overcome huge challenges in cancer therapy. Wiley Interdiscip Rev Syst Biol Med. 2014 Mar;6(2):201-8. doi:10.1002/wsbm.1254. 

Roukos DH. Genome network medicine: new diagnostics and predictive tools. Expert Rev Mol Diagn. 2013 Sep;13(7):643-6. doi: 10.1586/14737159.2013.820540.

Ku CS, Polychronakos C, Tan EK, Naidoo N, Pawitan Y, Roukos DH, Mort M, Cooper DN. A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease. Mol Psychiatry. 2013 Feb;18(2):141-53. doi: 10.1038/mp.2012.58.

Roukos DH, Baltogiannis GG, Katsouras CS, Bechlioulis A, Naka KK, Batsis C, Liakakos T, Michalis LK. Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery. Curr Pharm Des. 2014;20(1):11-22. 

Ku CS, Roukos DH. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices. 2013 Jan;10(1):1-6. doi: 10.1586/erd.12.63.

Lianos GD, Vlachos K, Zoras O, Katsios C, Cho WC, Roukos DH. Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther. 2014 Mar 24;7:491-500.

Lianos GD, Roukos DH. From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. Future Oncol. 2014 Feb;10(2):145-8. doi: 0.2217/fon.13.252. 

Roukos D. Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. Pharmacogenomics J. 2013 Jun;13(3):205-8. doi: 10.1038/tpj.2012.51.

Roukos DH, Baltogiannis GG, Baltogiannis G. Mapping inherited and somatic variation in regulatory DNA: new roadmap for common disease clinical discoveries. Expert Rev Mol Diagn. 2013 Jul;13(6):519-22. doi: 10.1586/14737159.2013.811908.

Ku CS, Cooper DN, Iacopetta B, Roukos DH. Integrating next-generation sequencing into the diagnostic testing of inherited cancer predisposition. Clin Genet. 2013 Jan;83(1):2-6. doi: 10.1111/cge.12028.

Roukos DH, Ku CS. Clinical cancer genome and precision medicine. Ann Surg Oncol. 2012 Nov;19(12):3646-50. doi: 10.1245/s10434-012-2542-9.  

Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.  Pharmacogenomics J. 2011 Apr;11(2):81-92. doi:10.1038/tpj.2010.81.

 

PubMed:

PubMed Link